ArticleAging clinical and experimental research2025
Associations between sarcopenia and its developed status with chronic lung disease in the middle-aged and older Chinese people.
Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between sarcopenia and chronic lung disease (CLD) has not been widely studied. We conducted a retrospective cohort study using the China Health and Retirement Longitudinal Study (CHARLS) data to investigate the relationship between sarcopenia status and its developed status and CLD in the middle-aged and older Chinese people.
methodWe selected 4444 participants over the age of 45 from CHARLS in 2011. Sarcopenia status was defined according to the Asian Working Group for Sarcopenia 2019 (AWGS 2019) criteria. CLD was defined as the presence of physician-diagnosed chronic lung disease. We retrospectively assessed their sarcopenia during 2011 and 2013, which were classified into never and newly developed sarcopenia, and these participants were followed from 2013 to 2018.
resultsDuring the 2011-2018 follow-up, 554 (12.4%) CLD events were identified. The new incidence rate of CLD in the sarcopenia group, newly developed sarcopenia group, low muscle mass alone group respectively 17.9% (54/302), 17.3% (39/226), and 13.8% (80/576). In the longitudinal analysis, individuals with sarcopenia [HR (95% CI): 1.468(1.068-2.017)] (P<0.01), newly developed sarcopenia [HR (95% CI): 1.486(1.031-2.141)] (P<0.05) and low muscle mass alone [HR (95% CI):1.555(1.174-2.059)] (P<0.01) were more likely to have new onset CLD.
conclusionSarcopenia, newly developed sarcopenia, and low muscle mass alone were associated with higher CLD risk among middle-aged and older Chinese adults. Therefore, early prevention and treatment of sarcopenia and avoiding its progression may help decrease the incidence of CLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.